Eli Lilly and Company (LLY)
Healthcare
Drug Manufacturers - General
1,148.80 $
-0.5%
vs. previous close
Closing price · As of: 31. Jul 2026
Eli Lilly and Company (LLY) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q1 26), "Revenue" came in at 19,799 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8,312 | 9,499 | 9,353 | 8,768 | 11,303 | 11,439 | 13,533 | 12,729 | 15,558 | 17,601 | 19,292 | 19,799 | 72,250 | |
| 1,807 | 1,860 | 1,788 | 1,674 | 2,170 | 2,171 | 2,404 | 2,224 | 2,448 | 3,008 | 2,884 | 3,577 | 11,917 | |
| 6,505 | 7,639 | 7,565 | 7,095 | 9,133 | 9,268 | 11,129 | 10,504 | 13,110 | 14,593 | 16,408 | 16,222 | 60,333 | |
| 2,357 | 2,409 | 2,563 | 2,523 | 2,711 | 2,734 | 3,023 | 2,734 | 3,336 | 3,466 | 3,802 | 3,510 | 14,114 | |
| 1,810 | 1,688 | 1,810 | 1,836 | 2,003 | 1,984 | 2,309 | 2,362 | 2,648 | 2,741 | 3,344 | 2,934 | 11,666 | |
| 4,166 | 4,098 | 4,372 | 4,359 | 4,714 | 4,719 | 5,331 | 5,096 | 5,984 | 6,206 | 7,633 | 7,372 | 27,195 | |
| 2,338 | 3,541 | 3,193 | 2,736 | 4,419 | 4,550 | 5,798 | 5,408 | 7,126 | 8,386 | 8,775 | 8,850 | 33,138 | |
| 120 | 125 | 138 | 180 | 184 | 193 | 225 | 244 | 249 | 180 | 123 | 332 | 884 | |
| 2,089 | 427 | 2,509 | 2,536 | 3,517 | 1,588 | 5,039 | 3,456 | 6,776 | 7,232 | 8,265 | 8,850 | 31,124 | |
| 326 | 485 | 319 | 293 | 550 | 618 | 629 | 697 | 1,116 | 1,650 | 1,629 | 1,454 | 5,849 | |
| 1,763 | -57 | 2,190 | 2,243 | 2,967 | 970 | 4,410 | 2,759 | 5,661 | 5,583 | 6,636 | 7,396 | 25,275 | |
| 2,576 | 963 | 3,035 | 3,116 | 4,115 | 2,248 | 5,748 | 4,163 | 7,504 | 7,882 | 8,388 | 9,691 | 33,465 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.